Most of the therapeutic concepts developed by RECARDIO are based on the mechanism of increasing the levels of SDF-1 in cardiac tissue.
The safety of RECARDIO’s lead program REC-01, including the DPP-IV inhibitor dutogliptin as therapeutic drug, which is being developed for the treatment of acute myocardial infarction (AMI), has already been proven in man up to Phase 3 studies. The Phase 2B clinical study will start in 2017 following the completion of a Phase 1 pharmacokinetic and dose ranging study.
REC-02 for congestive heart failure (CHF) will be the next project to enter clinical Phase 2 development.
Programs REC-03 and REC-04 have not yet been disclosed by the company.